Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 28, 2007; 13(24): 3374-3379
Published online Jun 28, 2007. doi: 10.3748/wjg.v13.i24.3374
Published online Jun 28, 2007. doi: 10.3748/wjg.v13.i24.3374
Group | Tumor | Tumor inhibitory | weight | ||
Volume (cm3) | rate | (g) | |||
Pre-treatment | Post- treatment | (%) | Pre-treatment | Post-treatment | |
BF1 | 43.50 ± 5.09 | 35.21 ± 12.51ac | 79.3 | 20.94 ± 1.00 | 21.39 ± 1.62e |
BF2 | 42.92 ± 4.10 | 49.83 ± 11.46ac | 70.7 | 20.03 ± 1.16 | 21.48 ± 1.10e |
BF3 | 43.00 ± 2.97 | 83.99 ± 24.63a | 50.7 | 21.06 ± 0.94 | 21.57 ± 1.14e |
ADM | 42.93 ± 4.23 | 55.17 ± 16.13a | 67.6 | 21.00 ± 1.00 | 18.90 ± 0.77 |
NS | 43.37 ± 4.82 | 170.39 ± 25.29 | - | 20.95 ± 1.07 | 20.40 ± 1.23 |
- Citation: Han KQ, Huang G, Gu W, Su YH, Huang XQ, Ling CQ. Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol 2007; 13(24): 3374-3379
- URL: https://www.wjgnet.com/1007-9327/full/v13/i24/3374.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i24.3374